Kidney Dosimetry in 777 Patients During Lu-DOTATATE Therapy: Aspects on Extrapolations and Measurement Time Points

Overview

Journal EJNMMI Phys

Specialty Radiology

Date 2020 Dec 9

PMID 33296054

Citations 20

Authors

Mattias Sandstrom

Nanette Freedman

Katarzyna Fross-Baron

Tanweera Kahn

Anders Sundin

Affiliations

Soon will be listed here.

Abstract

Purpose: Fractionated peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize PRRT to the individual patient. Accordingly, absorbed doses to organs at risk need to be calculated during PRRT, based on serial measurements of radioactivity distribution utilizing SPECT/CT. The dosimetry should be based on as few measurements as possible, while still retaining reliable results. The main aim of the present work was to calculate the fractional contribution of the extrapolations of the curve fits for the absorbed dose calculations to the kidneys. The secondary aim was to study agreement between absorbed dose (AD) and the effective half-life (t) for the kidneys, estimated by means of measurements at one or two time points, in comparison to our current method employing three time points.

Methods: In 777 patients with disseminated neuroendocrine tumors undergoing PRRT, SPECT/CT over the abdomen was acquired at 1, 4, and 7 days after Lu-DOTATATE infusion. The absorbed dose to the kidneys was calculated from SPECT/CT radioactivity distribution data, and the t and fractional contributions of the extrapolations were estimated, utilizing data from one, two, and three time points, respectively.

Results: The fractional contributions from extrapolations before day 1 measurement and after day 7 measurement were approximately 26% and 11%, respectively. The mean differences in absorbed dose, based on one, two, and three time points were small, but with high method dependence for individual patients. The differences in estimated t were small when it was based on measurements at days 1 and 7, but high for days 1 and 4 time points.

Conclusion: When assessing simplifications of methods for calculation of the absorbed dose to the kidneys, it was of the uttermost importance to incorporate the fractional contribution for the extrapolations included in the reference method. Measurements at an early and a late time point were found most important. An intermediate measurement contributes with an idea of the goodness of the fit.

Citing Articles

On the reduction of imaging time-points for dosimetry in radionuclide therapy.

Gustafsson J, Taprogge J EJNMMI Phys. 2025; 12(1):14.

PMID: 39909959 PMC: 11799503. DOI: 10.1186/s40658-025-00721-y.

Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B EJNMMI Res. 2024; 14(1):110.

PMID: 39557730 PMC: 11574229. DOI: 10.1186/s13550-024-01163-w.

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to Lutetium.

Ramonaheng K, Qebetu M, Ndlovu H, Swanepoel C, Smith L, Mdanda S Front Nucl Med. 2024; 4:1355912.

PMID: 39355215 PMC: 11440950. DOI: 10.3389/fnume.2024.1355912.

The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience.

Piscopo L, Zampella E, Volpe F, Gaudieri V, Nappi C, Di Donna E Curr Oncol. 2024; 31(9):5617-5629.

PMID: 39330044 PMC: 11431754. DOI: 10.3390/curroncol31090416.

Estimation of kidney doses from [Lu]Lu-DOTA-TATE PRRT using single time point post-treatment SPECT/CT.

Spink S, Gillett D, Heard S, Harper I, Casey R, Aloj L EJNMMI Phys. 2024; 11(1):68.

PMID: 39052172 PMC: 11272758. DOI: 10.1186/s40658-024-00665-9.

References

Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L . Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005; 46 Suppl 1:99S-106S. View

Jahn U, Ilan E, Sandstrom M, Garske-Roman U, Lubberink M, Sundin A . 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors. Neuroendocrinology. 2019; 110(7-8):662-670. DOI: 10.1159/000504001. View

Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H . Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2009; 37(2):212-25. DOI: 10.1007/s00259-009-1216-8. View

Del Prete M, Buteau F, Arsenault F, Saighi N, Bouchard L, Beaulieu A . Personalized Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2018; 46(3):728-742. DOI: 10.1007/s00259-018-4209-7. View

Stabin M, Sparks R, Crowe E . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023-7. View

Ilan E, Sandstrom M, Wassberg C, Sundin A, Garske-Roman U, Eriksson B . Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015; 56(2):177-82. DOI: 10.2967/jnumed.114.148437. View

Bolch W, Eckerman K, Sgouros G, Thomas S . MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009; 50(3):477-84. DOI: 10.2967/jnumed.108.056036. View

Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols L . Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med. 2005; 46 Suppl 1:92S-8S. View

Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C . Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010; 54(1):37-51. View

10.

Delker A, Ilhan H, Zach C, Brosch J, Gildehaus F, Lehner S . The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors. Mol Imaging Biol. 2015; 17(5):726-34. DOI: 10.1007/s11307-015-0839-3. View

11.

Guerriero F, Ferrari M, Botta F, Fioroni F, Grassi E, Versari A . Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. Biomed Res Int. 2013; 2013:935351. PMC: 3705840. DOI: 10.1155/2013/935351. View

12.

Sundlov A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P . Individualised Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017; 44(9):1480-1489. PMC: 5506097. DOI: 10.1007/s00259-017-3678-4. View

13.

Sandstrom M, Ilan E, Karlberg A, Johansson S, Freedman N, Garske-Roman U . Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Phys. 2015; 2(1):24. PMC: 4883125. DOI: 10.1186/s40658-015-0127-y. View

14.

Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M . Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004; 31(7):1038-46. DOI: 10.1007/s00259-004-1571-4. View

15.

Sandstrom M, Garske-Roman U, Johansson S, Granberg D, Sundin A, Freedman N . Kidney dosimetry during Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. Acta Oncol. 2017; 57(4):516-521. DOI: 10.1080/0284186X.2017.1378431. View

16.

Kwekkeboom D, Teunissen J, Bakker W, Kooij P, de Herder W, Feelders R . Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23(12):2754-62. DOI: 10.1200/JCO.2005.08.066. View

17.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

18.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17):2416-23. DOI: 10.1200/JCO.2010.33.7873. View

19.

Bergsma H, Konijnenberg M, van der Zwan W, Kam B, Teunissen J, Kooij P . Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016; 43(10):1802-11. PMC: 4969358. DOI: 10.1007/s00259-016-3382-9. View

20.

Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B . Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2012; 54(1):33-41. DOI: 10.2967/jnumed.112.107524. View